The Future Of Drug Trials Might Be Virtual AI Patients

AI-generated digital twins are revolutionizing drug research, potentially saving the biopharma industry billions annually. These computer-generated patient models predict health outcomes without treatment, enabling more efficient clinical trials. Companies like Unlearn.ai are developing technology to reduce sample sizes, cut enrollment time, and save millions in costs. This approach is particularly valuable for pediatric, oncology, and rare disease trials. While data quality and cultural adoption challenges persist, digital twins are increasingly trusted and delivering value in clinical research.